Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Cash from Financing Activities (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Cash from Financing Activities data on record, last reported at -$1.6 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 66.63% year-over-year to -$1.6 million; the TTM value through Sep 2025 reached -$18.1 million, down 5.55%, while the annual FY2024 figure was -$23.8 million, 472.34% down from the prior year.
  • Cash from Financing Activities reached -$1.6 million in Q3 2025 per UTMD's latest filing, up from -$4.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $19000.0 in Q1 2022 and bottomed at -$8.1 million in Q4 2021.
  • Average Cash from Financing Activities over 5 years is -$2.9 million, with a median of -$1.1 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 102.0% in 2022, then tumbled 5621.05% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$8.1 million in 2021, then soared by 88.6% to -$920000.0 in 2022, then decreased by 16.41% to -$1.1 million in 2023, then tumbled by 623.34% to -$7.7 million in 2024, then surged by 78.82% to -$1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$1.6 million in Q3 2025, -$4.5 million in Q2 2025, and -$4.2 million in Q1 2025.